Pre-made Odronextamab benchmark antibody ( Bispecific mAb, anti-MS4A1/CD20;CD3E therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-391

Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-391-1mg 1mg Inquiry
GMP-Bios-ab-391-10mg 10mg Inquiry
GMP-Bios-ab-391-100mg 100mg Inquiry
GMP-Bios-ab-391-xmg ＞100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody
INN Name Odronextamab
TargetCD20;CD3E
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2019
Year Recommended2020
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions ActiveFollicular lymphoma;B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma
Conditions Discontinuedna
Development Techna